id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S4958 R12999 |
De Lorenzo (Controls unexposed, disease free), 2020 | Malformations | at least 1st trimester | retrospective cohort | unexposed, disease free excluded | Adjustment: No |
7.00 [0.57;85.39] C excluded (control group) |
2/12 1/36 | 3 | 12 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S4959 R13005 |
De Lorenzo (Controls unexposed, sick), 2020 | Malformations | at least 1st trimester | retrospective cohort | unexposed, sick | Adjustment: No | 16.58 [0.73;376.16] C | 2/12 0/32 | 2 | 12 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S4995 R13095 |
Drechsel, 2020 | Major congenital malformations | 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 1.59 [0.06;41.24] C | 0/14 1/66 | 1 | 14 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S4952 R12991 |
Moens (Controls exposed to Vedolizumab), 2020 | Congenital anomalies (NOS) | at least 1st trimester | retrospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.51 [0.11;2.37] C excluded (control group) |
4/162 3/64 | 7 | 162 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S4951 R12986 |
Moens (Controls unexposed, sick), 2020 | Congenital anomalies (NOS) | at least 1st trimester | retrospective cohort | unexposed, sick | Adjustment: No | 1.35 [0.30;6.13] C | 4/162 3/163 | 7 | 162 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S3072 R4708 |
Duricova, 2019 | Congenital malformations | during pregnancy (anytime or not specified) excluded | retrospective cohort | unexposed, disease free | Adjustment: No |
0.82 [0.28;2.40] C excluded (exposition period) |
7/72 8/69 | 15 | 72 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S4997 R13101 |
Fu - Etanercept, 2019 | Congenital malformation (major or minor) | 1st trimester | randomized controlled trial | unexposed, sick | Adjustment: Randomisation | 1.59 [0.14;17.92] C | 2/85 1/67 | 3 | 85 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S3066 R4667 |
Chaparro, 2018 | Congenital malformations (NOS) | 3 months (or more) before pregnancy or during pregnancy excluded | retrospective cohort | unexposed, sick | Adjustment: No before conception and/or during pregnancy |
2.10 [1.02;4.33] C excluded (exposition period) |
21/388 12/453 | 33 | 388 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S3123 R11336 |
De Lima, 2018 | Major congenital abnormalities | at least 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 0.79 [0.01;43.11] C | 0/15 0/12 | 0 | 15 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S3093 R4771 |
Luu, 2018 | Malformations | during pregnancy (anytime or not specified) excluded | retrospective cohort (claims database) | exposed to other treatment, sick | Adjustment: No |
0.98 [0.72;1.33] C excluded (exposition period) |
49/799 303/4,836 | 352 | 799 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S4098 R11330 |
Carman - Etanercept (Controls unexposed, disease free), 2017 | Major malformations | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed, disease free excluded | Adjustment: No |
0.95 [0.49;1.85] C excluded (control group) |
11/210 59/1,078 | 70 | 210 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S4099 R11331 |
Carman - Etanercept (Controls unexposed, sick), 2017 | Major malformations | during pregnancy (anytime or not specified) excluded | retrospective cohort (claims database) | unexposed, sick | Adjustment: No |
1.08 [0.57;2.05] C excluded (exposition period) |
11/210 94/1,932 | 105 | 210 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S4106 R11333 |
Chambers - Adalimumab (Controls unexposed, sick, ADA only), 2017 | Major birth defects among all pregnancies | at least 1st trimester | prospective cohort | unexposed, sick | Adjustment: Yes | 0.91 [0.37;2.23] | -/- -/- | - | - |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S3009 R11339 |
Hoxha, 2017 | Congenital malformation | 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 0.43 [0.02;7.66] C | 1/24 1/11 | 2 | 24 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S3194 R11328 |
Bröms a (Controls unexposed, disease free), 2016 | Any major birth defect | 3 months or more before pregnancy or1st trimester | population based cohort retrospective | unexposed, disease free excluded | Adjustment: No |
1.53 [1.12;2.08] C excluded (control group) |
43/683 52,592/1,250,192 | 52,635 | 683 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S3193 R11329 |
Bröms a (Controls unexposed, sick), 2016 | Any major birth defect | 3 months or more before pregnancy or1st trimester excluded | population based cohort retrospective | unexposed, sick | Adjustment: Yes |
1.32 [0.93;1.82] excluded (exposition period) |
43/683 1,019/21,549 | 1,062 | 683 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S3070 R4688 |
De Lima (Controls unexposed, disease free), 2016 | Congenital Abnormalities | 1st and 2nd trimester | prospective cohort | unexposed, disease free | Adjustment: No | 1.04 [0.31;3.49] C | 3/83 28/804 | 31 | 83 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S3069 R4679 |
Agosti, 2015 | Congenital malformations (severe or not) | during pregnancy (anytime or not specified) excluded | retrospective cohort | unexposed, sick | Adjustment: No |
1.00 [0.18;5.53] C excluded (exposition period) |
3/24 3/24 | 6 | 24 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S4104 R11334 |
Chambers - Etanercept, 2015 | Major birth defects in live born infants | at least 1st trimester | prospective cohort | unexposed, sick | Adjustment: Yes | 2.77 [1.04;7.35] | -/- -/- | - | - |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S2888 R4104 |
Weber-Schoendorfer, 2015 | All birth defects | 1st trimester | prospective cohort | unexposed, disease free | Adjustment: Yes | 1.64 [1.10;2.60] | 52/423 87/1,393 | 139 | 423 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S4074 R11335 |
Cooper, 2014 | Major congenital malformations | 1st trimester | retrospective cohort (claims database) | unexposed, sick | Adjustment: Yes | 1.59 [0.30;8.47] | 2/56 4/171 | 6 | 56 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S2897 R11337 |
Diav-Citrin (Controls exposed to other treatments), 2014 | Major malformations | 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.72 [0.16;3.12] C excluded (control group) |
3/65 5/79 | 8 | 65 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S2893 R11338 |
Diav-Citrin (Controls unexposed, disease free), 2014 | Major malformations | 1st trimester | prospective cohort | unexposed, disease free | Adjustment: No | 1.98 [0.51;7.69] C | 3/65 8/336 | 11 | 65 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S3037 R4576 |
Seirafi, 2014 | Congenital malformations | 3 months (or more) before pregnancy or during pregnancy excluded | retrospective cohort | unexposed, sick | Adjustment: No before conception and/or during pregnancy |
0.25 [0.03;2.42] C excluded (exposition period) |
1/118 3/90 | 4 | 118 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S3014 R11332 |
Casanova, 2013 | Congenital malformations (NOS) | 3 months (or more) before pregnancy or during pregnancy excluded | retrospective cohort | exposed to other treatment, sick | Adjustment: No |
4.58 [0.28;74.22] C excluded (exposition period) |
1/60 1/271 | 2 | 60 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S13730 R53470 |
Viktil (Controls exposed to other treatments), 2012 | Major malformations | 3 months or more before pregnancy or1st trimester | population based cohort propective | exposed to other treatment, sick excluded | Adjustment: No |
0.34 [0.02;5.67] C excluded (control group) |
0/40 50/1,421 | 50 | 40 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S13731 R53472 |
Viktil (Controls unexposed, NOS), 2012 | Major malformations | 3 months or more before pregnancy or1st trimester excluded | population based cohort propective | unexposed (general population or NOS) | Adjustment: No |
0.38 [0.02;6.18] C excluded (exposition period) |
0/40 5,000/154,976 | 5,000 | 40 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S3017 R4524 |
Schnitzler (Controls unexposed, disease free), 2011 | Malformations (NOS) | 3 months (or more) before pregnancy or during pregnancy | prospective cohort | unexposed, disease free excluded | Adjustment: No before conception and/or during pregnancy |
4.11 [0.16;103.53] C excluded (control group) |
1/42 0/56 | 1 | 42 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S3018 R4523 |
Schnitzler (Unexposed control, sick), 2011 | Malformations (NOS) | 3 months (or more) before pregnancy or during pregnancy excluded | prospective cohort | unexposed, sick | Adjustment: No before conception and/or during pregnancy |
1.88 [0.11;30.81] C excluded (exposition period) |
1/42 1/78 | 2 | 42 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S2916 R13111 |
Verstappen, 2011 | Congenital malformations | early pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 1.80 [0.24;13.44] C | 2/32 2/56 | 4 | 32 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 13 studies | 1.57 [1.16;2.14] | 206 | 971 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Controls unexposed, sick; 2: Controls unexposed, sick; 3: Controls unexposed, sick, ADA only; 4: Controls unexposed, disease free; 5: Controls unexposed, disease free;
Asymetry test p-value = 0.9888 (by Egger's regression)
slope=0.4506 (0.2033); intercept=0.0051 (0.3584); t=0.0144; p=0.9888
excluded 3017, 13730, 2897, 3194, 4098, 4958, 4952